Optimising hypoxia PET imaging and its applications in guiding targeted radiation therapy for non‐small cell lung cancer: a scoping review

Abstract

IntroductionNon‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related death. Definitive treatment includes chemotherapy and radiation therapy. Tumour hypoxia impacts the efficacy of these treatment modalities. Novel positron‐emission tomography (PET) imaging has been developed to non‐invasively quantify hypoxic tumour subregions, and to guide personalised treatment strategies. This review evaluates the reliability of hypoxia imaging in NSCLC in relation to various tracers, its correlations to treatment‐related outcomes, and to assess if this imaging modality can be meaningfully applied into radiation therapy workflows.MethodsA literature search was conducted on the Medline (Ovid) and Embase databases. Searches included terms related to ‘hypoxia’, ‘positron‐emission tomography’, ‘magnetic resonance imaging’ and ‘lung cancer’. Results were filtered to exclude studies prior to 2011, and animal studies were excluded. Only studies referring to a confirmed pathology of NSCLC were included, while disease staging was not a limiting factor. Full‐text English language and translated literature examined included clinical trials, clinical cohort studies and feasibility studies.ResultsQuantification of hypoxic volumes in a pre‐treatment setting is of prognostic value, and indicative of treatment response. Dosimetric comparisons have highlighted potential to significantly dose escalate to hypoxic volumes without risk of additional toxicity. However, clinical data to support these strategies are lacking.ConclusionHeterogenous study design and non‐standardised imaging parameters have led to a lack of clarity regarding the application of hypoxia PET imaging in NSCLC. PET imaging using nitroimidazole tracers is the most investigated method of non‐invasively measuring tumour hypoxia and has potential to guide hypoxia‐targeted radiation therapy. Further clinical research is required to elucidate the benefits versus risks of dose‐escalation strategies.